Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints.
Saved in:
| Title: | Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints. |
|---|---|
| Authors: | Reilly MM; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK., Herrmann DN; Department of Neurology, University of Rochester, Rochester, NY., Pareyson D; Unit of Rare Neurodegenerative and Neurometabolic Diseases, Department of Clinical Neurosciences, Fondazione IRRCCS Istituto Neurologico Carlo Besta, Milan, Italy., Scherer SS; Department of Neurology, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA., Finkel RS; Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, TN., Züchner S; Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL., Burns J; Sydney School of Health Sciences, University of Sydney, Sydney, Australia., Shy ME; Department of Neurology, Carver College of Medicine, University of Iowa, Iowa, IA. |
| Source: | Annals of neurology [Ann Neurol] 2023 May; Vol. 93 (5), pp. 906-910. Date of Electronic Publication: 2023 Mar 21. |
| Publication Type: | Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
